Neurocrine biosciences announces settlement of ingrezza abbreviated new drug application (anda) litigation

San diego , nov. 13, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix), a leading neuroscience-focused biopharmaceutical company, today announced that is has resolved all patent litigation related to lawsuits resulting from abbreviated new drug applications (andas) brought by companies seeking approval to market a generic version of ingrezza® (valbenazine) prior to the expiration of applicable neurocrine patents.  as part of the resolution of these lawsuits, four companies have the right to sell generic versions of ingrezza in the united states beginning march 1, 2038, or earlier under certain customary circumstances.
NBIX Ratings Summary
NBIX Quant Ranking